Leap Therapeutics Reports Third Quarter 2018 Business Update and Financial Results


“Our team has executed extremely well over the past quarter, rapidly enrolling multiple clinical trials and presenting impressive clinical and preclinical data for both of our programs. We are excited about the potential for our DKN-01 antibody in patients with esophagogastric cancer, both in combination with KEYTRUDA® (pembrolizumab) and with paclitaxel. We believe that the emerging response and disease control rates, and now the progression-free survival and overall survival data, reflect outcomes that are clinically meaningful to patients with very difficult to treat cancer and are greater than what has previously been demonstrated with approved single agents”, commented Christopher K. Mirabelli, Ph.D, President and Chief Executive Officer of Leap Therapeutics. In addition, we look forward to presenting data from the studies of our TRX518 antibody in …

[Read on via official release]

Source: US SEC
View full document: